Changshan Pharmaceutical announced that the company recently received a notice that the company's drug heparin sodium injection has obtained a drug registration certificate issued by the Bolivian Drug Administration. The specification is 5ml and is valid until April 9, 2031. This drug is mainly used to prevent thrombosis or embolic diseases. This registration approval has had a positive impact on the company's expansion into overseas markets. Currently, the company's overseas sales revenue for heparin formulation products accounts for a low proportion of the company's total revenue.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.